Review of the evidence: prevalence of medical conditions in the United States population with serious mental illness.
Review of the evidence: prevalence of medical conditions in the United States population with serious mental illness.
复制标题
DOI：
10.1016/j.genhosppsych.2015.03.004
复制
发表时间：
2015-05
影响因子：
7
通讯作者：
Daumit GL
中科院分区：
文献类型：
--
作者：
Janssen EM;McGinty EE;Azrin ST;Juliano-Bult D;Daumit GL
严重精神疾病（SMI）患者因可预防的疾病而过早死亡的比率很高，但这一群体在流行病学调查中的代表性不足，我们缺乏对这一群体中肥胖和糖尿病等疾病患病率的国家估计。我们进行了一项全面的综述，以综合估计SMI人群中15种疾病的患病率。我们回顾了2000年1月至2012年8月在同行评审文献中发表的研究。如果研究评估了100名或更多美国成年精神分裂症或双相情感障碍患者的患病率，则纳入研究。共有57项研究被纳入该综述。对于大多数疾病，流行率估计值差异很大。例如，肥胖患病率的估计范围为26%至55%。这种变化似乎是由于测量差异（例如，自我报告与临床测量）和研究人群的潜在差异所致。很少有研究评估SMI患者的代表性社区样本的患病率。在许多研究中，患有SMI的人群中的医疗状况的患病率高于美国总体人群。筛查和监测这些条件应该是常见的做法，在临床设置服务的人与SMI。
Persons with serious mental illness (SMI) have high rates of premature mortality from preventable medical conditions, but this group is underrepresented in epidemiologic surveys and we lack national estimates of the prevalence of conditions such as obesity and diabetes in this group. We performed a comprehensive review to synthesize estimates of the prevalence of 15 medical conditions among the population with SMI. We reviewed studies published in the peer-reviewed literature from January 2000-August 2012. Studies were included if they assessed prevalence in a sample of 100 or more US adults with schizophrenia or bipolar disorder. 57 studies were included in the review. For most medical conditions, the prevalence estimates varied considerably. For example, estimates of obesity prevalence ranged from 26% to 55%. This variation appeared to be due to differences in measurement (e.g. self-report versus clinical measures) and underlying differences in study populations. Few studies assessed prevalence in representative, community samples of persons with SMI. In many studies, the prevalence of medical conditions among the population with SMI was higher than among the overall US population. Screening for and monitoring of these conditions should be common practice in clinical settings serving persons with SMI.